Comparison of antibodies and carbohydrates to target vaccines to human dendritic cells via DC-SIGN

Biomaterials

Volumn 33, Issue 16, 2012, Pages 4229-4239

  Cruz, Luis J ^a   Tacken, Paul J ^a   Pots, Jeanette M ^a   Torensma, Ruurd ^a   Buschow, Sonja I ^a   Figdor, Carl G ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Antigenicity; Drug delivery; Immune response; Immunostimulation; Nanoparticle

Indexed keywords

ANTIGENICITY; C-TYPE LECTINS; CLASS I; DENDRITIC CELLS; GLYCOSYLATED; HUMAN DENDRITIC CELLS; IMMUNE RESPONSE; IMMUNOSTIMULATION; LIPOARABINOMANNANS; NATURAL RECEPTORS; PROINFLAMMATORY CYTOKINES; SURFACE COATINGS; SURFACE MOLECULES; VACCINATION STRATEGY; VACCINE CARRIERS;

ANTIBODIES; ANTIGENS; CARBOHYDRATES; CELLS; COATINGS; DISEASES; DRUG DELIVERY; LIGANDS; NANOPARTICLES;

VACCINES;

ANTIBODY; CARBOHYDRATE; CD209 ANTIGEN; DRUG CARRIER; GLYCOPROTEIN GP 120; GLYCOSYLATED PROTEIN; HUMAN IMMUNODEFICIENCY VIRUS PROTEIN; LIPOARABINOMANNAN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; NANOCOATING; NANOPARTICLE; SIALYL LEWIS X ANTIGEN; TOLL LIKE RECEPTOR; VACCINE;

ARTICLE; CELL CULTURE; CELL MATURATION; CONTROLLED STUDY; DEGRADATION; DENDRITIC CELL; DRUG DELIVERY SYSTEM; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN GLYCOSYLATION; PROTEIN MODIFICATION; T LYMPHOCYTE ACTIVATION;

ANTIBODIES; CARBOHYDRATES; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CELL ADHESION MOLECULES; HISTOCOMPATIBILITY ANTIGENS CLASS I; HUMANS; KINETICS; LECTINS, C-TYPE; LYMPHOCYTE ACTIVATION; RECEPTORS, CELL SURFACE; TOLL-LIKE RECEPTORS; VACCINES;

EID: 84858798196     PISSN: 01429612     EISSN: 18785905     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2012.02.036     Document Type: Article

References (34)

1. Tacken P.J., de Vries I.J., Torensma R., Figdor C.G. Dendritic-cell immunotherapy: from ex vivo loading to in vivo targeting. Nat Rev Immunol 2007, 7:790-802.
2. Bonifaz L.C., Bonnyay D.P., Charalambous A., Darguste D.I., Fujii S., Soares H., et al. In vivo targeting of antigens to maturing dendritic cells via the DEC-205 receptor improves T cell vaccination. J Exp Med 2004, 199:815-824.
3. Boscardin S.B., Hafalla J.C.R., Masilamani R.F., Kamphorst A.O., Zebroski H.A., Rai U., et al. Antigen targeting to dendritic cells elicits long-lived T cell help for antibody responses. J Exp Med 2006, 203:599-606.
4. Hawiger D., Inaba K., Dorsett Y., Guo M., Mahnke K., Rivera M., et al. Dendritic cells induce peripheral T cell unresponsiveness under steady state conditions in vivo. J Exp Med 2001, 194:769-779.
5. Tacken P.J., Zeelenberg I.S., Cruz L.J., van Hout-Kuijer M.A., van de Glind G., Fokkink R.G., et al. Targeted delivery of Toll-like receptor ligands to human and mouse dendritic cells strongly enhances adjuvanticity. Blood 2011, 10.1182/blood201107367615.
6. Cruz L.J., Tacken P.J., Fokkink R., Joosten B., Stuart M.C., Albericio F., et al. Targeted PLGA nano- but not microparticles specifically deliver antigen to human dendritic cells via DC-SIGN in vitro. J Control Release 2010, 144:118-126.
7. Cruz L.J., Tacken P.J., Bonetto F., Buschow S.I., Croes H.J., Wijers M., et al. Multimodal imaging of nanovaccine carriers targeted to human dendritic cells. Mol Pharm 2011, 8:520-531.
8. Moris A., Nobile C., Buseyne F., Porrot F., Abastado J.P., Schwartz O. DC-SIGN promotes exogenous MHC-I-restricted HIV-1 antigen presentation. Blood 2004, 103:2648-2654.
9. Sanchez-Navarro M., Rojo J. Targeting DC-SIGN with carbohydrate multivalent systems. Drug News Perspect 2010, 23:557-572.
10. Singh S.K., Stephani J., Schaefer M., Kalay H., Garcia-Vallejo J.J., den Haan J., et al. Targeting glycan modified OVA to murine DC-SIGN transgenic dendritic cells enhances MHC class I and II presentation. Mol Immunol 2009, 47:164-174.
11. Gringhuis S.I., den Dunnen J., Litjens M., van der Vlist M., Geijtenbeek T.B.H. Carbohydrate-specific signaling through the DC-SIGN signalosome tailors immunity to Mycobacterium tuberculosis, HIV-1 and Helicobacter pylori. Nat Immunol 2009, 10:1081-1088.
12. Hodges A., Sharrocks K., Edelmann M., Baban D., Moris A., Schwartz O., et al. Activation of the lectin DC-SIGN induces an immature dendritic cell phenotype triggering Rho-GTPase activity required for HIV-1 replication. Nat Immunol 2007, 8:569-577.
13. Geijtenbeek T.B.H., Torensma R., van Vliet S.J., van Duijnhoven G.C.F., Adema G.J., van Kooyk Y., et al. Identification of DC-SIGN, a novel dendritic cell-specific ICAM-3 receptor that supports primary immune responses. Cell 2000, 100:575-585.
14. Tacken P.J., de Vries I.J., Gijzen K., Joosten B., Wu D., Rother R.P., et al. Effective induction of naive and recall T cell responses by targeting antigen to human dendritic cells via a humanized anti-DC-SIGN antibody. Blood 2005, 106:1278-1285.
15. Tacken P.J., Joosten B., Reddy A., Wu D., Eek A., Laverman P., et al. No advantage of cell-penetrating peptides over receptor-specific antibodies in targeting antigen to human dendritic cells for cross-presentation. J Immunol 2008, 180:7687-7696.
16. Pitarque S., Herrmann J.L., Duteyrat J.L., Jackson M., Stewart G.R., Lecointe F., et al. Deciphering the molecular bases of Mycobacterium tuberculosis binding to the lectin DC-SIGN reveals an underestimated complexity. Biochem J 2005, 392:615-624.
17. Schreibelt G., Benitez-Ribas D., Schuurhuis D., Lambeck A.J.A., van Hout-Kuijer M., Schaft N., et al. Commonly used prophylactic vaccines as an alternative for synthetically produced TLR ligands to mature monocyte-derived dendritic cells. Blood 2010, 116:564-574.
18. Houghten R.A., Bray M.K., Degraw S.T., Kirby C.J. Simplified procedure for carrying out simultaneous multiple hydrogen fluoride cleavages of protected peptide resins. Int J Pept Protein Res 1986, 27:673-678.
19. Tel J., Lambeck A.J.A., Cruz L.J., Tacken P.J., de Vries I.J., Figdor C.G. Human Plasmacytoid dendritic cells phagocytose, process, and present exogenous particulate antigen. J Immunol 2010, 184:4276-4283.
20. Yang J., Cao X., Sun C., Wu X., Li L. Sensitive determination of carbohydrates by fluorimetric method with Ce(IV) and sodium triphosphate. J Fluoresc 2004, 14:275-279.
21. Cruz L.J., Tacken P.J., Fokkink R., Figdor C.G. The influence of PEG chain length and targeting moiety on antibody-mediated delivery of nanoparticle vaccines to human dendritic cells. Biomaterials 2011, 32:6791-6803.
22. Geijtenbeek T.B.H., Gringhuis S.I. Signalling through C-type lectin receptors: shaping immune responses. Nat Rev Immunol 2009, 9:465-479.
23. Hong P.W.P., Flummerfelt K.B., de Parseval A., Gurney K., Elder J.H., Lee B. Human immunodeficiency virus envelope (gp120) binding to DC-SIGN and primary dendritic cells is carbohydrate dependent but does not involve 2G12 or cyanovirin binding sites: Implications for structural analyses of gp120-DC-SIGN binding. J Virol 2002, 76:12855-12865.
24. Trinchieri G., Sher A. Cooperation of Toll-like receptor signals in innate immune defence. Nat Rev Immunol 2007, 7:179-190.
25. Cambi A., Lidke D.S., Arndt-Jovin D.J., Figdor C.G., Jovin T.M. Ligand-conjugated quantum dots monitor antigen uptake and processing by dendritic cells. Nano Lett 2007, 7:970-977.
26. Ludwig I.S., Lekkerkerker A.N., Depla E., Bosman F., Musters R.J., Depraetere S., et al. Hepatitis C virus targets DC-SIGN and L-SIGN to escape lysosomal degradation. J Virol 2004, 78:8322-8332.
27. Tacken P.J., Ginter W., Berod L., Cruz L.J., Joosten B., Sparwasser T., et al. Targeting DC-SIGN via its neck region leads to prolonged antigen residence in early endosomes, delayed lysosomal degradation and cross-presentation. Blood 2011, 118:4111-4119.
28. Belizaire R., Unanue E.R. Targeting proteins to distinct subcellular compartments reveals unique requirements for MHC class I and II presentation. Proc Natl Acad Sci U S A 2009, 106:17463-17468.
29. Burgdorf S., Kautz A., Bohnert V., Knolle P.A., Kurts C. Distinct pathways of antigen uptake and intracellular routing in CD4 and CD8 T cell activation. Science 2007, 316:612-616.
30. Tsuji T., Matsuzaki J., Kelly M.P., Ramakrishna V., Vitale L., He L.Z., et al. Antibody-targeted NY-ESO-1 to mannose receptor or DEC-205 in vitro elicits dual human CD8+ and CD4+ T cell responses with broad antigen specificity. J Immunol 2011, 186:1218-1227.
31. Park C.G., Takahara K., Umemoto E., Yashima Y., Matsubara K., Matsuda Y., et al. Five mouse homologues of the human dendritic cell C-type lectin, DC-SIGN. Int Immunol 2001, 13:1283-1290.
32. Cheong C., Matos I., Choi J.H., Dandamudi D.B., Shrestha E., Longhi M.P., et al. Microbial stimulation fully differentiates monocytes to DC-SIGN/CD209+ dendritic cells for immune T cell areas. Cell 2010, 143:416-429.
33. Schaefer M., Reiling N., Fessler C., Stephani J., Taniuchi I., Hatam F., et al. Decreased pathology and prolonged survival of human DC-SIGN transgenic mice during mycobacterial infection. J Immunol 2008, 180:6836-6845.
34. Anthony R.M., Kobayashi T., Wermeling F., Ravetch J.V. Intravenous gammaglobulin suppresses inflammation through a novel TH2 pathway. Nature 2011, 475:110-113.